• AFT Pharmaceuticals are a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter, prescription and hospital.

    AFT's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs.

  • Maxigesic global growth continues

    AFT Pharmaceuticals (‘AFT’) has reached agreement with privately-owned Swiss headquartered multinational pharmaceutical company, Acino Pharma AG (‘Acino’), to out-license the product line of its patented combination painkiller, Maxigesic, to a further 69 countries.

    To view the announcements please click here.

  • NZX

    Shares in AFT Pharmaceuticals Limited (“AFT”), began trading on the NZX Main Board and ASX on 22 December 2015, following the successful IPO that raised $35.6 million through the issue and sale of New and existing shares.

    To view the announcements please click here.

Analyst Coverage

Firm Analyst Contact Details Reports
First NZ Capital/Credit Suisse Greg Main Direct line: +64 4 474 4061
Mobile: +64 21 937 271
Fax: +64 4 496 5311
Email: greg.main@fnzc.co.nzOpens in new window
Website: www.firstnzcapital.co.nzOpens in new window
Edison Group Maxim Jacobs

Dennis Hulme
Telephone: +1 646 653 7027
Email: mjacobs@edisongroup.comOpens in new window

Telephone: +61 (0)2 8211 0429
Email: DHulme@edisongroup.comOpens in new window

Website: www.edisongroup.comOpens in new window

AFT is followed by the analysts listed above. Any opinions, forecasts and estimates regarding AFT’s performance made by these analysts are theirs alone and are made independently of AFT. They do not represent opinions, forecasts, estimates or predictions of AFT, its directors or its management.   AFT does not by its reference to the analyst details and links to publicly available reports above imply its endorsement of or agreement with any information, conclusion or recommendations made by an analyst.  AFT does not provide any assurance that information stated in any analyst report is correct.